RT Journal Article
SR Electronic
T1 Characteristics and Outcomes of Multisystem Inflammatory Syndrome in Children: A Multicenter, Retrospective, Observational Cohort Study in Mexico
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.16.23285979
DO 10.1101/2023.02.16.23285979
A1 González-García, Nadia
A1 Yamazaki-Nakashimada, Marco Antonio
A1 Márquez-González, Horacio
A1 Miranda-Novales, Guadalupe
A1 Neme Díaz, Gonzalo Antonio
A1 Prado Duran, Sandhi Anel
A1 Velázquez, Antonio Luévanos
A1 Castilla-Peon, Maria F.
A1 Sánchez Duran, Miguel Alejandro
A1 Márquez Aguirre, Martha Patricia
A1 Villasis-Keever, Miguel Angel
A1 Aragón Nogales, Ranferi
A1 Enríquez, Carlos Núñez
A1 Martinez Bustamante, Maria Elena
A1 Argüello, Carlos Aguilar
A1 de los Santos, Jesús Ramírez
A1 Pérez Barrera, Alejandra
A1 Palacios Cantú, Lourdes Anais
A1 Mondragón, Jesús Membrila
A1 Alvarado, Paloma Vizcarra
A1 Jiménez Juárez, Rodolfo Norberto
A1 López, Víctor Olivar
A1 Chávez, Adrián López
YR 2023
UL http://medrxiv.org/content/early/2023/02/23/2023.02.16.23285979.abstract
AB Multisystem inflammatory syndrome in children temporally associated with coronavirus disease 2019 (MIS-C), a novel hyperinflammatory condition secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with severe outcomes such as coronary artery aneurysm and death. This multicenter, retrospective, observational cohort study including eight centers in Mexico, aimed to describe the clinical characteristics and outcomes of patients with MIS-C. Patient data were evaluated using latent class analysis to categorize patients into three phenotypes: toxic shock syndrome-like (TSSL)-MIS-C, Kawasaki disease-like (KDL)-MIS-C, and nonspecific MIS-C (NS-MIS-C). Risk factors for adverse outcomes were estimated using multilevel mixed-effects logistic regression. The study included 239 patients with MIS-C, including 61 (26%), 70 (29%), and 108 (45%) patients in the TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C groups, respectively. Fifty-four percent of the patients were admitted to the intensive care unit, and 42%, 78%, and 41% received intravenous immunoglobulin, systemic glucocorticoids, and anticoagulants, respectively. Coronary artery dilatation and aneurysm were found in 5.7% and 13.2% of the patients, respectively. The rate of mortality due to SARS-CoV-2-related factors was 4.6%. Delay of ≥10 days in hospital admission was associated with coronary artery aneurysm or dilatation (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2–2.0). Age ≥ 10 years (OR 5.6, 95% CI 1.4–2.04), severe underlying condition (OR 9.3, 95% CI 2.8–31.0), platelet count < 150,000/mm3 (OR 4.2, 95% CI 1.2–14.7), international normalized ratio > 1.2 at admission (OR 3.8, 95% CI 1.05–13.9), and serum ferritin concentration > 1500 mg/dL (OR 52, 95% CI 5.9–463) were risk factors for death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that this study received funding from Hospital Infantil de Mexico Federico Gomez. The funder was not involved in the study design, collection, analysis, or interpretation of data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Federico Gomez Mexico Children's Hospital Institutional Review Board (approval no. HIM-2022-015) and the local ethics review board of the remaining participating centers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets are available on request to NGG (nadiag.him@gmail.com)